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Abstract
The HIV-1 protein, Tat has been implicated in AIDS pathogenesis however, the amount of circulating Tat is believed to be
very low and its quantification has been difficult. We performed the quantification of Tat released from infected cells and
taken up by neurons using high performance capillary electrophoresis. This is the first report to successfully measure the
amount of Tat in neurons and places Tat as a key player involved in HIV-associated neurocognitive disorders.
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Introduction
HIV infection is pandemic with more than 30 million people
infected worldwide. In the USA following the onset of AIDS, 10–
15% patients per year develop HAND, a neurocognitive and motor
abnormality during the later stage of infection [1]. However, in
recent years, in vitro and ex vivo studies have attempted to characterize
the mechanisms that underlie the relationship between HIV
infection and HAND. Available data suggest that the mechanism(s)
leading to damage in the brain of AIDS patients might involve the
combined effects of more than one neurotoxic factor [2]. In
particular, evidence suggests that viral proteins (e.g., Tat) secreted
from HIV-1 infected cells [3] are among these factors. Although the
use of HAART reduces the frequency of HAND, this treatment
might be less efficient in brain tissues and therefore in the treatment
of HAND [4]. In fact, the quality of life of some HIV patients
continues to be diminished by residual, milder forms of neurocog-
nitive impairment. Tat is a viral transactivator of the HIV-1
promoter [5,6]. It binds the cyclin T1 component of the positive
transcription elongation factor b, recruits cyclin-dependent kinase 9
to elongating HIV transcripts and induces phosphorylation of the C-
terminal domain of RNA polymerase II by Cdk9 [7]. Tat is mainly
active inthe nucleusand issecretedathigh-levelsinvitro[8].Secreted
Tat can cause direct or indirect injury to neurons, thus Tat may
contribute to neurological impairments observed in HIV patients on
successful HAART regimens. The neurotoxicity of Tat involves
prolonged elevations in intracellular calcium [9] followed by an
increase in reactive oxygen species and activation of the apoptotic
pathway [10]. Tat also promotes activation of monocytes,
macrophages and astrocytes triggering the release of inflammatory
factors, which can lead to neuronal damage [11]. All attempts
leading to inhibit Tat-mediated neurodegeneration both in vitro and
in vivo have failed. It hasbeen shown that at a concentration as low as
1 nanomolar and 2 to 20 femtomolar, HIV-1 Tat can significantly
induce apoptosis of PC12 or rat neuronal degeneration, respectively
[12]. In addition, Tat induces apoptosis in human neuroblastoma
cells [13], in human fetal neurons [14] and in embryonic rat
hippocampal neurons [12]. However, the exact amounts of Tat
released from HIV-infected cells or taken up by non-infected cells
remain unclear. With the introduction of proteomics and the
development of these techniques mainly high performance capillary
electrophoresis (HPCE) this measurement is now possible.
In this study, we used HPCE to determine the amount of Tat
taken up by neuronal cells that can lead to neuronal degeneration.
This information may be valuable for the development of
therapeutic agents that protect the CNS neurons from toxic viral
factors thus lessening the severity of HAND.
Methods
High performance capillary electrophoresis (HPCE)
HPCE allows for separation of molecules based on their sizes,
structure, charges and hydrophobic potential. For fluorescence
derivatization, 10 ml of recombinant Tat protein or biological
samples, 10 mlo fp h o s p h a t eb u f f e ra n d0 . 5mlo f6 0m M4 - F l u o r o -
7-nitro-2, 1,3-benzoxadiazole (NBD-F) were used. The mixture was
heated at 55uC for 15 min in the dark. The Beckman P/ACE MDQ
capillary electrophoresis instrument (Fullerton, CA) equipped with a
laser-induced fluorescence detector was used for quantitative analysis
of Tat protein in biological samples. LIF detection was performed in
an uncoated fused silica CE column of 50 mm inner diameter and
60 cm in length with 50 cm from inlet to the detection window
(Polymicro Technologies, Phoenix, AZ). The injection was applied
hydro dynamically at a pressure of 0.4 p.s.i. for 8 seconds. The
separation voltage was 25 kV. Data were collected and processed
using the Beckman P/ACE 32 Karat software version 7.0.
Cell culture and transfection assays
Human microglia and neuroblastoma (SH-SY5Y) cell lines
[15,16] and primary human neurons (HN) [purchased from
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in DMEM +10% FBS. Confluent SH-SY5Y cells were re-plated at
1–5610
5 cells/ml and induced to differentiate by treatment with
10 mM retinoic acid (Sigma, St. Louis, MO) for 7 d with medium
changes every two days. For all of the experiments, cells were
serum starved for 6 h in the presence of 10 mM RA prior to
treatment with rTat or transfection after which complete fresh
media was added.
Cells were transfected with 0.1 mg of LTR-luc reporter plasmid
or treated with increasing amount of recombinant Tat protein
(rTat), co-transfected with 0.25 mg of Tat expression cDNA or
transduced with Ad-null or Ad-Tat [10]. The cells were also
transfected with 1.0 mg of CMV-b-galactosidase plasmid using
Nucleofector kit V (Amaxa). The amount of DNA used was
normalized with pcDNA3 vector plasmid. Cell extracts were
prepared 48 h after transfection and luciferase and b-gal
determined. All values were normalized against b-gal values
measured as previously described [16].
HIV-1 infection
The human U-937 monocytic cell line [17] was maintained in
RPMI +10% FBS, 100 units/ml penicillin, 50 mg/ml streptomy-
cin-G. Cells in log phase were infected with JR-FL strains of HIV-
1 as follows [18]. Fifty nanograms of p24-containing virus stock
were added to every 1610
6 cells. Cells were incubated with virus
stock in a small volume of serum free media for 2 h at 37uC. The
cells were then washed twice with PBS and fresh medium
containing 2% of FBS was added (500,000 cells/ml).
P24 ELISAs were performed for tissue culture supernatants as
described by the manufacturer (Coulter-Immunotech, Wesbrook,
ME). Each sample was assayed over a 10,000-fold range of
dilution, to ensure quantitation, was based on an OD value within
the linear range of the standards. Neuronal cells were treated
(infected) with supernatant prepared from HIV-1-infected cells
(concentration =10 MOI) for 24 hr and processed as described in
the Results section.
Cell Extracts Preparation
SH-SY5Y cells were cultured under different conditions (6
rTat, or 6 supernatant prepared from HIV-infected or control
cells) after which cells were lysed in lysis buffer [10]. Protein lysates
were diluted to the appropriate/required volume and used for
HPCE assay.
Cell death assays
SH-SY5Y cells were mock-treated or treated with 1 pg/ml of
rTat for 24 hrs. The cells were then collected and incubated with
0.4% trypan blue dye (Invitrogen Life Technologies) for 4 min,
before washing with PBS and counting. Unstained (viable) and
stained (dead) cells were counted separately using hemacytometer.
In parallel, untreated or Tat-treated SH-SY5Y cells were also
plated, fixed and stained with mouse anti-microtubule-associated
protein-2 (MAP-2) or anti-Tubulin mAb (Cell Signal) followed by
Cy3-conjugated rabbit-anti-mouse secondary Ab (Abcam). Scion
Image software was used to quantify MAP-2 reactivity after Tat
treatment.
Neurites Outgrowth Analysi
SH-SY5Y cells (mock-treated or treated with 1 pg/ml of rTat)
were grown on chamber slides for 24 hrs, fixed in 4%
paraformaldehyde, washed and then stained for 3 min in a 4%
Trypan blue methanol/acetic acid/water solution. Anti-tubulin
antibody was also used. The cells were observed at different
magnifications through phase contrast microscopy (convolution).
The images acquired on different samples were analyzed to
quantify 3 different parameters: sample area covered by cells,
neurite extension to cell area ratio, and mean of single neurite
length. Single and total neurite analyses were done on areas of
0.30 mm
2 in order to obtain a more accurate measure of neurite
length. The experiment was performed in triplicate.
Statistical analyses were assessed by 1-way ANOVA within
groups (same time of cell culture, same culture medium), followed
by a Tukey posttest using GraphPad Prism version 4.00 for
Windows, GraphPad Software (San Diego CA, USA) to evaluate
neurite lengths. Two-way ANOVA was used for comparisons
between groups, followed by a Bonferroni post-test. Differences
were considered statistically significant for p , 0.05.
2DE-based Differential Proteomics Technology
U-937 cells were infected with HIV-1 and the supernatant was
added to neuronal cells. Proteins from the Tat-detected peak were
collected and separated by 2DE gel via two IPG strips (pH of Tat
is 6.12) followed by Sypro-Ruby fluorescence staining. Next, In-
Gel Trypsin Digestion-Differentially expressed spots were excised
and destaining of the excised gel pieces was performed. The
detected spots were analyzed by MALDI-TOF. Matching the
calibrated peptide mass values within NCBInr protein databases
identified Tat protein.
Results and Discussion
Several reports demonstrated the presence of HIV-1 Tat
proteins in human neurons in vitro and in vivo [18] however, the
exact amount of Tat released from HIV-infected cells and subject
to neuronal uptake remained unclear. We have now addressed this
question using high performance capillary electrophoresis (HPCE).
First, we measured the amount of Tat released from the human
monocytic cell line, U937, infected with JR-FL strain of HIV-1
and taken up by the neuronal cell line, SH-SY5Y. Briefly, HIV-1
was added to 1610
6 U937 cells for 10 days [19]. On day 10 post-
infection, supernatant from the U937 cells was collected and
ultracentrifuged to remove virus, while leaving Tat and other
secreted viral proteins. Three ml (10 MOI) of this supernatant was
added to SH-SY5Y cells. After 24 h, supernatants and cell lysates
collected from HIV-1-infected U937 or non-infected SH-SY5Y,
respectively, were processed for detection of Tat by HPCE [20].
To first establish a standard curve for calibration, solutions
containing recombinant Tat protein (101aa) (rTat) (highly pure toxin-
free Tat purchased from Immuno Diagnostics, Inc.; Woburn, MA), were
prepared at concentrations ranging from 2 to 50 pg and
concentrate in 10 ml. As shown in Fig. 1A (blue), approximately
2 pg represent the assay’s detection limit for Tat. Next, the
amount of Tat was measured in the supernatant from infected
U937 cells (Fig. 1B, red) and was found to be approximately 2 fold
greater than the rTat at 2 pg in the standard curve (blue). To
determine the approximate concentration of Tat in U937 cells,
4 pg of rTat was added to the U937 infected supernatant (green).
Tat was also detected in neuronal extracts from neurons exposed
to supernatant from HIV infected U937 cells (Fig. 1B, panel C,
red). To calculate the amount of Tat in lysates, non-infected
extracts were spiked with 1 pg of rTat (Fig. 1C, green). The
amount of Tat detected in SH-SY5Y neuronal cells was about
2 pg/ml (Fig. 1C, red) as compared to spiked lysates (Fig. 1C,
green). As a negative control, proteins from non-infected SH-
SY5Y cells were used (Fig. 1C, black). Uptake of Tat was also
measured using SH-SY5Y cells exposed to 2 pg of rTat for 24 h
(Fig. 1C, blue) after which cell proteins were prepared. Tat
Measurement of HIV-1 Tat Protein in Neurons
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the conclusion that at least 50% of the released Tat is taken up by
neuronal cells [8]. This conclusion correlates with the results
obtained and shown in panel B (red). Note that the rationale for
choosing SH-SY5Y cells is that they mirror pathways involved in
neurodegenerative process associated with HIVE [21]. It should
be added that difference in time observed in Fig. 1 is due to the
nature of samples analyzed, where in sample 1, rTat was the only
component to be analyzed while in other panels Tat was issued
from either the supernatant of infected cells or from cell extracts
after adding the infected/isolated supernatant. Thus, the presence
of other proteins delayed the release of Tat and the presence of
additional peaks (e.g. Fig. 1B). Note that analyses of the additional
peaks from Fig. 1B did not reveal the presence of Tat protein and
therefore these peaks do not represent dimers or multimers Tat.
Similar results were obtained when using primary human
culture of neurons. Briefly, cells untreated (control), rTat-treated
(2 pg/ml) or treated with supernatant prepared from HIV-infected
cells were processed and the amount of Tat in these cells was
measured. Data shown in Figure 2 confirmed results presented in
Figure 1 and show that Tat was detected in treated cells and not in
the control. Similar results were obtained when using the CSF
from an HIV-1 negative, and an HIV-1 positive patient (data not
shown).
In order to confirm the presence of Tat in the cells, primary
human neurons were treated with supernatant from HIV-infected
cells, using 2DE-based Differential Proteomics Technology. Tat
protein was identified by matching the calibrated peptide mass
values within NCBInr protein databases and a Tat peptide
sequence LEPWKHPGSQPK was identified by the MS/MS
spectrum, confirming the presence of Tat protein in extracts
prepared from uninfected primary human neurons treated with
supernatant from HIV-infected cells. To validate our data, we
performed a Western blot analysis using anti-Tat antibody,
however, we were unable to detect Tat protein due to its small
amount (data not shown, ref. 10).
Since we have detected Tat in neuronal extracts, we next
examined its functionality using transfection of the HIV-1 LTR
reporter plasmid by nucleofection. Nucleofector technology allows
gene expression to start immediately, independently of cell
division. Thus nucleofected cells can be analyzed after an extremely short
incubation time. Human microglia and neuronal cells were
transfected with 0.5 mg of the HIV-1 reporter plasmid LTR-luc.
1 mg of CMV-b-gal was also included. After 24 h, rTat was added
(1 mg, 1 ng, or 1 pg/ml) followed by luciferase assay. rTat up
regulates the HIV-1 promoter in both cell lines (Fig. 2B, compare
columns 2–4 to 1 and 6–8 to 5). The functionality of rTat was also
determined in the neuronal cell line SH-SY5Y stably transfected
and expressing LTR-luc-IRES-GFP, which contains 2 reporter
genes, luciferase and green fluorescent protein (GFP) separated by
an internal ribosome entry site (IRES). SH-SY5Y cells were
transfected with 0.5 mg of Tat expression plasmid (Fig. 2C, lane 2),
or infected with 1 MOI of Ad-null (lane 3) or Ad-Tat (lane 4). Cells
were also treated with 1 pg/ml of rTat (lane 5) or with supernatant
from U937 cells infected with the JR-FL strain of HIV-1 (lane 6).
Luciferase assay shows that Tat activates the HIV-1 promoter in
neuronal cells compared to mock (Fig. 2C, lane 1) or Ad-null (lane
3). Activation of LTR by Tat ranged from 2-fold with rTat (lane 5)
to 13 fold with supernatant from infected cells (lane 6). These data
demonstrate the functionality of rTat, i.e., 1 pg/ml of rTat protein
activates the HIV-1 promoter. Our results correlate with the
previous reports of Tat activation of the HIV-1 LTR in neuronal
cells [22].
Next, we examined whether Tat affects neurites retraction, we
treated SH-SY5Y cells with rTat (1 pg/ml) for 24 h in duplicate
where one set was used to determine neurites retraction while the
other set was used to determine impact of Tat on microtubules.
Using anti-tubulin and DAPI staining to detect the neurites and
the cellular nuclei, respectively, we observe that treatment of the
neurons with Tat resulted in neurites retraction relative to
untreated cells (Fig. 3A). These findings agree with previous
reports where 2 - 20 femtomoles of Tat protein were shown to be
neurotoxic [8,23]. Importantly, our studies show a higher
concentration of Tat in neurons derived from the supernatant of
infected cells.
To study the effects of Tat on SH-SY5Y neurites, we used time-
lapse microscopy. The response dynamics were evaluated by
measuring neurites retraction distance. This was compared with
the initial length of the extended neurite, which varied between 4
and 25 mm. Images of retracted neurites show that most of them
Figure 1. High performance capillary electrophoresis analysis of Tat protein. A. Electropherograms showing different concentrations of
rTat in order to examine the sensitivity of the assay. B, C. Representative electropherograms comparing the amount of Tat in supernatant from
infected cells or from lysates from uninfected neuronal SH-SY5Y cells to which the supernatant was added.
doi:10.1371/journal.pone.0016148.g001
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(panel A, arrows). To determine the time course of neurites
retraction, we measured neurite length over 10 min after rTat
application. Between 1 and 2 min after exposure to 1 pg/ml of
rTat, neurites had retracted by 10.3% and 19.7%, respectively
[mean (SD)], p,0.01 compared with the untreated neurites that
showed almost no change in length. Neurites continued to retract
over time such that at 10 min post-Tat application neurites
retraction was almost 52.1%.
Alternatively, we sought to further examine the impact of Tat
treatment on microtubules using the second set of cells treated
with 1 pg/ml of rTat protein led to a marked reduction (75%) in
the Microtubule-associated protein 2 (MAP-2) reactivity (Fig. 3B),
compared with untreated cells (compare lanes 1 and 2). Note that
Figure 2. Measurement of Tat in primary human neurons (HN) and ability of rTat to activate HIV-1 gene expression. A. Representative
electropherograms comparing the amount of Tat in supernatant from infected cells (red) or from extracts from uninfected (black) HN cells to which
the supernatant was added. As a control, extracts were also prepared from rTat-treated cells (blue). B. Human microglia and SH-SY5Y cells were
transfected with 0.5 mg of LTR-Luc alone and treated with different concentrations of rTat. C. SH-SY5Y cells expressing the LTR-luc-IRES-GFP were
transfected with Tat expression plasmid, infected with Ad-null or Ad-Tat, or treated with rTat (1 pg/ml) or supernatant from infected cells. Cell
extracts were prepared 24 h (microglia) or 48 h (SH-SY5Y) after transfection and luciferase and b-gal determined. All values were normalized against
b-gal and represent mean of at least 3 experiments.
doi:10.1371/journal.pone.0016148.g002
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protein family and serve to stabilize microtubules (MT) growth
[24]. These results complement and confirm the data observed in
panel A with anti-tubulin regarding alteration of microtubules.
Finally, we investigated whether addition of Tat leads to cell death.
To that end, SH-SY5Y cells were treated with 1 pg/ml of rTat for
24 hrs after which the cells were stained with trypan blue and cell
death was assessed. Briefly, five cell areas were used (each contains
,100 cells) to count the number of dead cells. Interestingly, there was
approximately 4-fold increase in cell death as measured by trypan
blue exclusion in Tat-treated neurons when compared to untreated
cells (Fig. 3C, compare lanes 1 and 2) [25]. Results were significant
using statistical analysis as described in the Methods section.
In summary, neuronal degeneration remains a major problem
associated with HIV-1 infection of the CNS even with successful
HAART. In this regard, several factors, including the viral protein
Tat, are involved in the development of neuronal injury, however
the exact amount of circulating Tat protein remains unclear.
Despites the several attempts that aimed to measure the amount of
circulating Tat in cells, in human sera as well as in CSF [8,26,27],
the levels of circulating Tat protein remains unclear. Here using
capillary electrophoresis, we provided evidence to show for the
first time the presence and amount of viral protein Tat in neurons.
Taken together, our data showed that released Tat protein can be
taken up by neuronal cells and causes neuronal deregulation
through a pathway that remains to be identified. In this regard, we
recently demonstrated that Tat causes neuronal deregulation by
increasing the levels of secreted calcium, mitochondria deregula-
tion and axonal transport alteration (manuscript in preparation).
Further, our data presented in Figure 3 showed that Tat affects the
Figure 3. rTat cause dendritic retraction in SH-SY5Y. A. Phase contrast microscopy of SH-SY5Y cells either untreated or treated with rTat as
indicated. The cells were stained with DAPI (blue) and anti-tubulin (red) to mark the nucleus and the processes, respectively. B. Tat-induced neurites
retraction is time-dependent. Cell cultures were exposed to 1 pg/ml of rTat and assessed over 10 min. Values are expressed as percentage neurites
retraction. P,0.01 vs control (untreated) (ANOVA, followed by Bonferroni test). Values represent mean (SD), (n=15). C. Quantification of MAP-2
immunoreactivity revealed marked reduction (75%) in rTat-treated SH-SY5Y cells. D. Effect of rTat-treatment on SH-SY5Y neuronal death as assessed
by trypan blue exclusion.
doi:10.1371/journal.pone.0016148.g003
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lead to alteration of axonal transport and communication (Fig. 3A
and B). Therefore, the new method developed in this study clearly
demonstrated the limitation of the previous techniques used to
measure Tat in neuronal cells. It will also help in determining the
amount of other viral proteins in infected cells. Further
identification and measurement of Tat in non-infected cells may
also help in estimating the amount of antibodies that should be
used to neutralize the effect of Tat, which could lead to the
development of more efficient therapy.
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